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Since diabetes mellitus (DM) is one of the most common and serious endocrine metabolic disorders, it is important to elucidate
novel antidiabetic therapeutic agents from various sources, including natural products. Bee venom (BV) is a complex mixture
of proteins, peptides, and low molecular components, and melittin is the main constituent. Melittin is a peptide consisting of
26 amino acids with the sequence GIGAVLKVLTTGLPALISWIKRKRQQ. It has several important biological effects and has a
relatively low toxicity. Recent studies using animal models have confirmed that melittin has significant glucose and lipid lowering
activities by acting on several mechanistic pathways. The main antidiabetic activity of melittin is increasing insulin secretion
via depolarization of pancreatic 𝛽-cells. Other possible mechanisms may involve stimulation of phospholipase A
2
, increase of
glucose uptake, improving lipid profile, and/or reduction of inflammation.This review summarizes the various sources, proteomics,
biological roles, adverse effects, and medical applications of melittin and its mechanism of action in combating DM.
1. Introduction
Diabetes mellitus (DM) is a serious disease in which the
body cannot control the amount of sugar in circulation due
to either a deficiency of insulin secretion or a decreased
sensitivity of the tissues to insulin. There are two main types
of diabetes as follows: Type 1 and Type 2 [1]. Both types
can cause serious health complications, including kidney
failure, heart disease, blurred vision, ketoacidosis, peripheral
neuropathy, itchiness, fatigue, and even coma [2]. An insulin
deficiency leads to elevations of cholesterol, phospholipids,
and free fatty acids [3]. Therefore, it is important that an
ideal DM therapy should not only involve maintaining blood
glucose levels but also involve the regulation of the lipid
profile.
To treat DM, several antidiabetic drugs are used. How-
ever, these drugs are not without side effects and pose
an economic burden to the patient. Therefore, scientists
have turned to natural remedies, including honey and bee
products, such as bee venom (BV). BV is a complex mixture
of proteins, peptides, and lowmolecular components secreted
by theworker and the queen bees.Themain active constituent
of BV (apitoxin) is melittin, which has a relatively low toxicity
[4]. It exerts important effects on cells, such as hemolysis,
membrane depolarization and muscle contraction, cytotox-
icity, and phospholipase C and arachidonic acid following
phospholipaseA2 activation. In addition, it is also responsible
for various allergic reactions in the body and can suppress the
signal pathways of toll-like receptors (TLR2, TLR4), cluster
of differentiation (CD14), nuclear factor kappa-B essential
modulator (NEMO), and platelet-derived growth factor beta
(PDGFR𝛽). By suppressing these pathways, melittin dimin-
ishes the activation of p38, ERK1/2, AKT, and PLC𝛾1 and
the translocation of NF-𝜅B into the nucleus, consequently
leading to reduced inflammation in the skin, aorta, joints,
liver, and neuronal tissues [5].
BV proteins, mainly melittin, are also widely used in the
treatment of arthritis, frozen shoulder, diseases of the central
and peripheral nervous system (CNS, PNS), skin diseases,
heart and blood system related diseases, cancer, ulcer, colitis,
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Figure 1: Basicmechanismof insulin secretion and sequentialmechanistic pathway of BV (melittin) leading to an increase in insulin secretion
in pancreatic 𝛽-cells. (A) Blood glucose (>5mM in concentration) enters the 𝛽-cell through the glucose transporter (GLUT2). (B) ATP
production rapidly occurs as a result of glycolysis and respiration. (C)Then, ATP-sensitive K+ channels are closed, and K+ efflux is inhibited.
(D) Consequently, plasma membrane depolarizes, and (E) voltage-gated Ca2+ channels open. Finally, Ca2+ influx increases, which triggers
exocytosis of insulin granules. A Melittin directly depolarizes the cell membrane, B it increases Ca2+ inflow into the cell, C it promotes
more granule secretion, and D it increases insulin secretion into the blood stream. Note: phosphorus: P; calcium: Ca2+. Adapted from
https://www.dolcera.com/wiki/index.php?title=Diabetes products and services.
and neuritis [14, 15, 17, 19, 24–28]. Recent studies also con-
firmed thatmelittin can significantly reduce blood glucose via
insulin secretion and glucose uptake in animal models [21–
23]. These studies also reported that melittin has significant
lipid regulating activities by activating phospholipase A
2
.
Thus, melittin could be a potential therapeutic agent against
DM.
A number of reviews are available in the literature, which
focused on the miscellaneous pharmacological effects of BV
proteins [17, 29–37]. However, to date, reviews of the mech-
anisms by which BV contributes to the antidiabetic activity
are currently not available. In this review, we discussed the
principal activity of melittin (Table 1) and its antidiabetic
mechanism of actions (Figure 1).
2. Composition of Honeybee Venom
BV is a bitter colorless liquid (pH 4.5–5.5) that dries up easily
even at room temperature and is soluble inwater but insoluble
in alcohol and ammonium sulfate [5, 38, 39]. A bee can inject
up to 0.1mg venom via its stinger. It has been reported to
be similar to the toxin of the sea nettle [40]. The venom is
mainly produced in the abdomen of the worker bees and
originates from a mixture of acidic and basic secretions. It
is a complex mixture of proteins, in which some enzymes
(catalyzing specific reactions), some peptides (which consist
of two or more amino acids), and others, including a variety
of low molecular components, such as carbohydrates (2%
of venom dry weight), phospholipids (5% of venom dry
weight), amino acids (1% of venom dry weight), minerals (3-
4% of venom dry weight), and volatile compounds (5–8%
of venom dry weight) [15, 41], are present. Among these,
the main component comprises proteins and peptides, the
combination of which is commonly known as venom toxins.
3. Melittin
In a previous study, Danneels et al. determined the con-
stituents of 34 samples of venom toxins by using mass
spectrometry [42]. Among all of the honey proteins, the
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Table 1: Principal honeybee protein (melittin).
Bee venom protein name Melittin
Alternative names Allergen Api m 3, Allergen Api m III, Allergen Api m 4
Percentage of dry weight (%) 40–50
Sources
Honeybee Apis mellifera (honeybee), Apis mellifera carnica (Carniolan honeybee), Apis dorsata(giant honeybee), Apis florea (dwarf honeybee), Apis cerana (Indian honeybee)
Bee Osmia rufa (red mason bee)
Insect
Vespa magnifica (hornet), Polistes hebraeus (paper wasp), Polistes sp. (golden paper
wasp), Vespula maculifrons (eastern yellow jacket), Vespa velutina nigrithorax
(hornet)
Bacteria
Salmonella typhi, Pseudomonas fluorescens, Synechocystis sp., Aphanocapsa sp.,
Escherichia coli, Stenotrophomonas maltophilia, Pseudomonas maltophilia,
Xanthomonas maltophilia, Moellerella wisconsensis, Pseudomonas batumici,
Ralstonia solanacearum, Thioalkalivibrio nitratireducens, Klebsiella pneumonia,
Francisella sp., Brucella melitensis biotype 1, Ralstonia solanacearum, Bacteroides
xylanisolvens, Acinetobacter baumannii, Acinetobacter bereziniae, Sporomusa sp.,
Zunongwangia profunda, Leeuwenhoekiella blandensis, Cyclobacterium qasimii
M12-11b
Others
Rana arvalis (moor frog), Rana temporaria (European common frog), Rana tagoi
(Tago frog), Rana tagoi okiensis (Oki brown frog), Rana sakuraii (Japanese brown
frog), Naja oxiana (Central Asian Cobra) (Oxus cobra), Pardachirus pavoninus
(peacock sole)
Tissue specificity Expressed by the venom gland
Gene name MELT
Formula C
350
H
552
N
84
0
99
S
2
Total number of atoms 1087
Molecular weight (Dalton) 7584.8
Total length (amino acids) 70
Peptide length (amino acids) 26
Total sequence 10: MKFLVNVALV, 20: FMVVYISYIY, 30: AAPEPEPAPE, 40: PEAEADAEAD, 50:PEAGIGAVLK, 60: VLTTGLPALI, 70: SWIKRKRQQG
Peptide sequence 44–69: GIGAVLKVLTTGLPALISWIKRKRQQ
Theoretical isoelectric point (pI) 4.69
Subunit Monomer and homotetramer
Total number of negatively
charged residues (Asp + Glu) 9
Total number of positively
charged residues (Arg + Lys) 6
Extinction coefficient
(M−1cm−1) 9970, at 280 nm measured in water
Estimated half-life
(i) 30 hours (mammalian reticulocytes, in vitro)
(ii) >20 hours (yeast, in vivo)
(iii) >10 hours (Escherichia coli, in vivo)
Grand average of hydropathicity
(GRAVY) 0.239
Toxic dose LC (50) is 2.7 𝜇g/mL against killifish
Investigated biological functions
Major
(i) Hemolytic activity
(ii) Anti-inflammatory activity
(iii) Anticancer, antibacterial, antifungal, antiviral activities
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Table 1: Continued.
Others
(i) Inhibits well-known transport pumps (such as Na+-K+-ATPase, H+-K+-ATPase)
(ii) Activates phospholipase A
2
(iii) Diminishes membrane surface tension
(iv) Stimulates smooth muscle
(v) Lowers blood coagulation
(vi) Influences central nervous system (CNS)
(vii) Increases capillary permeability
Adverse effects
(i) Initiates various allergic reactions
(ii) Lyses erythrocytes
(iii) Creates cytotoxicity in human peripheral blood lymphocytes
(iv) Modulates gene expression related to apoptosis, DNA damage response, and
oxidative stress
Medical applications
(i) Arthritis
(ii) Cancer
(iii) Diseases of central and peripheral nervous systems
(iv) Skin diseases
(v) Heart and blood system related diseases
(vi) Frozen shoulder
(vii) Asthma, bronchitis
(viii) Colitis, ulcers
(xi) Others: ophthalmology, endocrinology, urology, gynecology,
otorhinolaryngology
Data sources and references
(i) Research Collaboratory for Structural Bioinformatics, Protein Data Bank (RCSB
PDB)
(ii) Protein Information Resource (PIR)
(iii) UniprotKB
(iv) [5–19]
Note. Lethal concentration: LC, three-dimensional: 3D, and nuclear magnetic resonance: NMR.
principal protein is confirmed to be melittin, which consti-
tutes approximately 40–50% of the venom dry weight [15].
Melittin consists mainly of a 26-amino-acid peptide with
no disulfide bridge in which the N-terminal part of the
molecule is predominantly hydrophobicwhile theC-terminal
is hydrophilic and is strongly basic [PMID: 10692322]. The
characteristics of melittin, including the sources, proteomics,
biological functions, adverse effects, and medical applica-
tions, are summarized in Table 1.
4. Previous Breakthroughs of Bee Venom’s
Role in Diabetes
Several epidemiological studies using animal models have
shown that the use of BV is associated with a lower DM
risk (Table 2). Kim et al. investigated whether BV can
prevent insulitis and the development of diabetes in nonobese
diabetic (NOD) female mice that have been subdivided into
control (𝑛 = 24) and BV (𝑛 = 24) treated groups [20]. BV
(purchased from Sigma, MO, USA) was injected at 0.5mg/kg
into the hind limb twice per week when the mice were
between 4 and 10 weeks of age. The cumulative incidences of
diabetes in the control and BV treated NOD mice were 58%
and 21%, respectively, at 25 weeks of age. Therefore, it was
postulated that BV treatment in NOD mice inhibits insulitis
and the onset and overall incidence of diabetes at an early age.
Another in vivo study conducted by Mousavi et al.
reported that Iranian BV (Apis mellifera) can lower blood
glucose and lipid levels in diabetic rats [21]. Adult male rats
(𝑛 = 18) weighing 200 ± 20 g were placed into the following
three random groups: control rats, alloxan monohydrated-
induced diabetic rats (150mg/kg intraperitoneally), and BV
treated rats (0.5mg/kg). In their experiment, BV was col-
lected from beehives using an electric shocker.
In addition to Apismellifera BV, BV from Apis cerana has
also been reported to have antidiabetic activity as reported
by Prakash and Bhargava [22]. In their study, the samples
were divided into test and control groups in which the test
group was categorized as “before” and “after” being stung by
Apis cerana bees. Their study also reported that Apis cerana
BV reduced blood cholesterol and triglyceride levels. Then,
Khulan AM and Chimedragcha [23] investigated the effects
of Mongolian BV on hyperglycemia and hyperlipidemia in
alloxan-induced diabetic rabbits [23]. For this study, chin-
chilla rabbits (𝑛 = 22) were divided into the following three
groups: control (𝑛 = 6), diabetic (𝑛 = 8), and BV treated
(𝑛 = 8) groups. To induce diabetes, an alloxanmonohydrated
solution (5%) was administered at 100mg/kg intravenously
via the marginal vein behind the ear over two minutes.
Meanwhile, the BV treated group received a bee sting on
their hind paw every other day following the confirmation
of diabetes. Their results also supported that BV significantly
lowers serum glucose levels and improves the lipid profile. All
of the researchers confirmed that the principal protein in BV,
melittin, is mainly responsible for the antidiabetic actions,
which was also confirmed by an in vitro test that indicated
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Table 2: In vivo studies of DM based on BV.
Venom
source
Animal
model Duration Dose Outcomes
Year,
reference
BV from
Sigma,
MO, USA
Mice 25 weeks 0.5mg/kg
(i) Inhibited insulitis
(ii) Inhibited onset and
cumulative incidence of diabetes
1999 [20]
Iranian
Honey BV
(Apis
mellifera)
Lewis rats 4 months 0.5mg/kg
(i) Increased serum insulin level
(ii) Decreased serum triglyceride
contents
(iii) Decreased serum total
cholesterol
2012 [21]
Apis
cerana BV Human
≈30
minutes
Apis cerana bees
(𝑛 = 8) sting the
groups
individually
(i) Decreased blood sugar
(ii) Decreased blood cholesterol
(iii) Decreased blood triglyceride
contents
(iv) Increased eosinophil count
2014 [22]
Mongolian
BV (Apis
mellifera)
Rabbits 14 days
A bee sting
(contains
0.2–0.5mL of
BV)
(i) Decreased blood glucose
levels
(ii) Decreased blood cholesterol
levels
(iii) Decreased low density
lipoproteins
(iv) Increased high density
lipoproteins
2015 [23]
that melittin can increase insulin secretion from pancreatic
𝛽-cells.
5. Antidiabetic Mechanism of
Actions of Melittin
DM is a syndrome of impaired carbohydrate, fat, and protein
metabolisms due to a combination of both hereditary and
environmental causes and is characterized by increased blood
glucose levels. In DM therapy, great attention is paid to
lowering blood glucose levels by increasing insulin secretion
and lipid regulating mechanisms of various medical agents,
including those from animal toxins. Melittin reduces blood
glucose levels by increasing insulin secretion from the 𝛽-cells
of the pancreas and facilitating glucose uptake [43]. It also
alleviates complications of DM by ameliorating lipid profiles
as verified by several studies [21–23].
Recent studies reported that various types of BV signif-
icantly reduce not only blood glucose levels but also total
cholesterol (Table 2). Melittin, which is present in BV, is
mainly responsible for the antidiabetic role as confirmed by
an in vitro test conducted by Morgan and Montague [43].
Melittin reduces blood glucose levels by several different
mechanisms, including depolarization of 𝛽-cell membranes,
increasing the extracellular calciumand calciumchannels [21,
44], activating cytosolic phospholipaseA2 [23, 45], increasing
glucose transporter lipid uptake into adipose tissues [23], and
suppression of 𝛽-cell inflammation [46].
Melittin initiates membrane depolarization to cause clo-
sure of the ATP-sensitive K+ channels. Thus, voltage-gated
Ca2+ channels are opened to promote increased insulin secre-
tion into the blood stream [43] (Figure 1). Melittin also pro-
motes insulin secretion by activating phospholipase A
2
[44].
The activated phospholipase A
2
promotes arachidonic acid
production, which, in turn, acts as a calcium transporter into
the 𝛽-cells to stimulate insulin secretion [47].
It is also reported that phospholipaseA
2
has an alternative
antidiabetic mode of action by increasing glucose uptake into
the adipose tissues rather than increasing insulin secretion.
Due to its enzymatic action, it can partially break down the
cell membrane of plasmatic lipoproteins [48]. This activity
leads to increased glucose transport and lipid uptake into the
adipose tissues through partial lyses of adipocyte membranes
and binding of a higher number of insulin molecules [49].
Meanwhile, phospholipaseA
2
also has a higher affinity for the
plasmatic lipoproteins, which leads to cytotoxic effects and
generation of free fatty acids and lysophospholipids. Thus,
circulating cholesterol in HDL is esterified and significantly
regulates lipid profiles [50].
Another in vivo study conducted by Kim et al. reported
that BV can prevent insulitis and the development of diabetes
in NOD mice due to its immune-modulating activities,
often attributed to an autoimmune process that damages
the pancreatic cells [20]. Their investigations also confirmed
that BV injections did not yield any side effects during the
experimental period, indicating its safety.
6. Future Directions
Since melittin is a small peptide of 26 amino acids, it
is often administered subcutaneously, which can lead to
several adverse reactions, including local erythema, swelling,
tenderness, itching, edema, malaise, flu-like symptoms, and
urticaria [15]. Althoughmelittin significantly reduces glucose
and cholesterol levels in the bloodstream, its toxicity must
be reduced before it can be used as an antidiabetic agent.
6 Journal of Chemistry
Computational bioinformatics and recombinant technology
may be used to produce various modified melittin with high
therapeutic effects and minimal toxicity. Further investiga-
tion should be carried out to (1) improve the procedure of
BV collections without killing the bees, (2) develop melittin
extraction methods to allow high yields of BV, and (3)
improve the preservation methods of BV to maintain its
efficacy.
7. Conclusion
This review article was prepared as a preliminary resource
to gather information on the potential of BV, specifically its
major active constituent melittin against diabetes mellitus. In
diabetes treatment, great consideration is given to lowering
blood glucose with various in vitro studies showing that bee
venom significantly reduces blood glucose levels via several
mechanisms. Nevertheless, there is still lack of adequate
in vivo studies done especially using pure melittin from
BV. Finally, due to the potential of melittin for reducing
blood glucose levels and total cholesterol by several different
mechanisms, it is concluded that melittin can have a great
impact in the near future in the treatment of diabetesmellitus.
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